Daclatasvir
J - Antiinfectives For Systemic Use -> J05 - Antivirals For Systemic Use -> J05A - Direct Acting Antivirals -> J05AX - Other Antivirals -> J05AX14 - Daclatasvir
Administration category:
Free
Medicine group:
antiviral
Brand name:
Daklinza
Standard dosages
| Weight | ROA | Load | Dosage |
|---|---|---|---|
|
ROA: po |
Load: - |
Dosage: 60mg 1 dd |
Kidney function
Renal elimination:
6.6%
Dosage:
independent on kidney function
Interactions
| Interaction with (ATC): | Interaction with: | Expected effect: |
|---|---|---|
|
Interaction with (ATC): J05AG03 - Efavirenz |
Interaction with: |
Expected effect: dosering daclatasvir naar 1 dd 90 mg |
|
Interaction with (ATC): J05AG01 - Nevirapine |
Interaction with: |
Expected effect: dosering daclatasvir naar 1 dd 90 mg |
|
Interaction with (ATC): J05AG04 - Etravirine |
Interaction with: |
Expected effect: dosering daclatasvir naar 1 dd 90 mg |
|
Interaction with (ATC): |
Interaction with: Sterke CYP3A4 remmer |
Expected effect: dosering daclatasvir naar 1 dd 30 mg |
Pregnancy
Due to the expiration of the alphanumeric classification for use in pregnancy and lactation, reference is made to the current, online information of the Teratology Information Service (TIS) of LAREB:
- http://www.lareb.nl//Teratologie/Naslagwerk-GZB/GZB---Zwangerschap#TOC_Middelen_bij6
- http://www.lareb.nl//Teratologie/Naslagwerk-GZB/GZB---Borstvoeding#TOC_Middelen_bij16
For individual advice, consult an expert on site.
Metadata
Swab vid: M-287669.1
Updated: 06/16/2019 - 20:05
Status: Published